Back

MCLA-128 ESMO Poster (October 2018)

Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)